These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 9214408)

  • 1. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
    Takahashi F; Finch JL; Denda M; Dusso AS; Brown AJ; Slatopolsky E
    Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of 19-nor-1,25(OH)2D2, a new analogue of calcitriol, on secondary hyperparathyroidism in uremic rats.
    Slatopolsky E; Finch J; Ritter C; Takahashi F
    Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S40-7. PubMed ID: 9808142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new analog of calcitriol, 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia.
    Slatopolsky E; Finch J; Ritter C; Denda M; Morrissey J; Brown A; DeLuca H
    Am J Kidney Dis; 1995 Nov; 26(5):852-60. PubMed ID: 7485144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential effects of 1,25-dihydroxy-vitamin D3 and 19-nor-1,25-dihydroxy-vitamin D2 on calcium and phosphorus resorption in bone.
    Finch JL; Brown AJ; Slatopolsky E
    J Am Soc Nephrol; 1999 May; 10(5):980-5. PubMed ID: 10232683
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p21WAF1 and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium.
    Cozzolino M; Lu Y; Finch J; Slatopolsky E; Dusso AS
    Kidney Int; 2001 Dec; 60(6):2109-17. PubMed ID: 11737585
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The roles of calcium and 1,25-dihydroxyvitamin D3 in the regulation of vitamin D receptor expression by rat parathyroid glands.
    Brown AJ; Zhong M; Finch J; Ritter C; Slatopolsky E
    Endocrinology; 1995 Apr; 136(4):1419-25. PubMed ID: 7895652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 1α,24(S)(OH)2D2 normalizes bone morphology and serum parathyroid hormone without hypercalcemia in 25-hydroxyvitamin D-1-hydroxylase (CYP27B1)-deficient mice, an animal model of vitamin D deficiency with secondary hyperparathyroidism.
    St-Arnaud R; Arabian A; Yu VW; Akhouayri O; Knutson JC; Strugnell SA
    J Endocrinol Invest; 2008 Aug; 31(8):711-7. PubMed ID: 18852532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.
    Slatopolsky E; Finch J; Denda M; Ritter C; Zhong M; Dusso A; MacDonald PN; Brown AJ
    J Clin Invest; 1996 Jun; 97(11):2534-40. PubMed ID: 8647946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Regulation of intestinal vitamin D receptor expression in experimental uraemia: effects of parathyroidectomy and administration of PTH.
    Szabó A; Schmutz A; Pesian S; Schmidt-Gayk H; Ritz E; Reichel H
    Nephrol Dial Transplant; 1998 Feb; 13(2):340-9. PubMed ID: 9509444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abnormal expression and regulation of vitamin D receptor in experimental uremia.
    Szabó A; Ritz E; Schmidt-Gayk H; Reichel H
    Nephron; 1996; 73(4):619-28. PubMed ID: 8856261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia.
    Slatopolsky E; Cozzolino M; Lu Y; Finch J; Dusso A; Staniforth M; Wein Y; Webster J
    Kidney Int; 2003 Jun; 63(6):2020-7. PubMed ID: 12753289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential effects of 19-nor-1,25-(OH)(2)D(2) and 1alpha-hydroxyvitamin D(2) on calcium and phosphorus in normal and uremic rats.
    Slatopolsky E; Cozzolino M; Finch JL
    Kidney Int; 2002 Oct; 62(4):1277-84. PubMed ID: 12234297
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New vitamin D analogs.
    Slatopolsky E; Finch J; Brown A
    Kidney Int Suppl; 2003 Jun; (85):S83-7. PubMed ID: 12753273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoregulation in the parathyroid glands by PTH/PTHrP receptor ligands in normal and uremic rats.
    Lewin E; Garfia B; Almaden Y; Rodriguez M; Olgaard K
    Kidney Int; 2003 Jul; 64(1):63-70. PubMed ID: 12787396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.
    Soliman E; Canaff L; Fox J; Hendy GN
    Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of 2-methylene-19-nor-(20S)-1 alpha-hydroxy-bishomopregnacalciferol (2MbisP), an analog of vitamin D, on secondary hyperparathyroidism.
    Slatopolsky E; Finch JL; Brown AJ; Ritter CS; Mizobuchi M; Plum LA; Clagett-Dame M; Sicinski RR; DeLuca HF
    J Bone Miner Res; 2007 May; 22(5):686-94. PubMed ID: 17444814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E; Weerts C; Thielan J; Horst R; Harter H; Martin KJ
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vitamin D prodrugs 1alpha(OH)D2, 1alpha(OH)D3 and BCI-210 suppress PTH secretion by bovine parathyroid cells.
    Brown AJ; Ritter CS; Knutson JC; Strugnell SA
    Nephrol Dial Transplant; 2006 Mar; 21(3):644-50. PubMed ID: 16221703
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V; Torregrosa V
    Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.